Cancer Family
Breast Neoplasm
CI-CAN-00000007Explore in graph →
Non-malignant2,894 active trials43 approved drugs310 evidence items
- NCIt
- C2910
- OncoTree
- BNNOS
- MeSH
- D000069584
- MeSH
- D001943
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000007Explore in graph →
Clinical trials
13,867 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02546232 | Improved Breast Cancer Therapy (I-BCT-1) in the Neoadjuvant and Metastatic Setting | active not recruiting | Phase 2 | 196 | Oslo University HospitalOTHER | 1 | Jun 4, 2025 | clinicaltrials |
| NCT05251714 | CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer | active not recruiting | Phase 1 / Phase 2 | 44 | Treadwell Therapeutics, IncINDUSTRY | 1 | May 18, 2025 | clinicaltrials |
| NCT05463601 | Mecapegfilgrastim for the Prevention of Dalpiciclib -Induced Neutropenia in Advanced Breast Cancer | active not recruiting | Phase 2 | 132 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | May 14, 2025 | clinicaltrials |
| NCT06957379 | Sirolimus for Injection (Albumin-bound) in Combination With Endocrine Therapy for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Who Have Failed Standard Therapy | active not recruiting | Phase 2 | 78 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | May 4, 2025 | clinicaltrials |
| NCT03161353 | Chemotherapy-free Trastuzumab and Pertuzumab in HER2-positive Breast Cancer: FDG-PET Response-adapted Strategy.(PHERGain) | active not recruiting | Phase 2 | 377 | MedSIROTHER | 7 | Apr 23, 2025 | clinicaltrials |
| NCT03594396 | Window of Opportunity Trial of Neoadjuvant Olaparib and Durvalumab for Triple Negative or Low ER+ Breast Cancer | active not recruiting | Phase 1 / Phase 2 | 54 | Seoul National University HospitalOTHER | 1 | Apr 17, 2025 | clinicaltrials |
| NCT04445844 | INCMGA00012 and Pelareorep for the Treatment of Metastatic Triple Negative Breast Cancer, IRENE Study | active not recruiting | Phase 2 | 25 | Mridula George, MDOTHER | 1 | Apr 4, 2025 | clinicaltrials |
| NCT05252988 | Three Antidiarrheal Strategies in HER2+/HR+ Early Breast Cancer Patients Treated With Extended Adjuvant Neratinib(DIANER) | active not recruiting | Phase 2 | 177 | Spanish Breast Cancer Research GroupOTHER | 1 | Apr 1, 2025 | clinicaltrials |
| NCT04802876 | Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors(ACROPOLI) | active not recruiting | Phase 2 | 184 | SOLTI Breast Cancer Research GroupOTHER | 1 | Mar 21, 2025 | clinicaltrials |
| NCT00999804 | Extension Study of Lapatinib Plus Herceptin With or Without Endocrine Therapy(HELEX) | active not recruiting | Phase 2 | 128 | Baylor Breast Care CenterOTHER | 1 | Mar 12, 2025 | clinicaltrials |
| NCT02547987 | Neoadjuvant Carboplatin and Docetaxel in Triple Negative Breast Cancer(CADENCE) | active not recruiting | Phase 2 | 25 | Mothaffar RimawiOTHER | 1 | Mar 12, 2025 | clinicaltrials |
| NCT05918133 | A Study of PM8002 Plus Nab-paclitaxel as First Line Therapy for TNBC | active not recruiting | Phase 1 / Phase 2 | 42 | Biotheus Inc.INDUSTRY | 1 | Mar 11, 2025 | clinicaltrials |
| NCT03324425 | Simvastatin Plus Dual Anti-HER2 Therapy for Metastatic Breast Cancer(SIMPHONY) | active not recruiting | Phase 2 | 5 | Baylor Breast Care CenterOTHER | 1 | Feb 27, 2025 | clinicaltrials |
| NCT04807192 | CMP-001 and Pre-operative Stereotactic Body Radiation Therapy (SBRT) in Early Stage Triple Negative Breast Cancer (TNBC) | active not recruiting | Phase 2 | 40 | Centre Hospitalier Universitaire VaudoisOTHER | 1 | Feb 27, 2025 | clinicaltrials |
| NCT03944434 | FACILE: FeAsibility of First-line RiboCIclib in OLdEr Patients with Advanced Breast Cancer(FACILE) | active not recruiting | Phase 2 | 116 | Fondazione Sandro PitiglianiOTHER | 1 | Feb 26, 2025 | clinicaltrials |
| NCT00248287 | PhII ICb With/Without Erbitux in MBC Pts(CA225200) | active not recruiting | Phase 2 | 154 | US Oncology ResearchINDUSTRY | 1 | Jan 29, 2025 | clinicaltrials |
| NCT02752685 | Phase II Study of Pembrolizumab and Nab-paclitaxel in HER-2 Negative Metastatic Breast Cancer | active not recruiting | Phase 2 | 70 | NYU Langone HealthOTHER | 1 | Jan 29, 2025 | clinicaltrials |
| NCT04215146 | A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study | active not recruiting | Phase 2 | 48 | Oncolytics BiotechINDUSTRY | 1 | Jan 16, 2025 | clinicaltrials |
| NCT02299999 | SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer(SAFIR02_Breast) | active not recruiting | Phase 2 | 1,460 | UNICANCEROTHER | 1 | Jan 15, 2025 | clinicaltrials |
| NCT03875573 | Neo-adjuvant Chemotherapy Combined With Stereotactic Body Radiotherapy to the Primary Tumour +/- Durvalumab, +/- Oleclumab in Luminal B Breast Cancer:(Neo-CheckRay) | active not recruiting | Phase 2 | 147 | Jules Bordet InstituteOTHER | 2 | Dec 20, 2024 | clinicaltrials |
| NCT03616886 | Paclitaxel + Carboplatin + Durvalumab With or Without Oleclumab for Previously Untreated Locally Recurrent Inoperable or Metastatic TNBC(SYNERGY) | active not recruiting | Phase 1 / Phase 2 | 129 | Jules Bordet InstituteOTHER | 2 | Dec 19, 2024 | clinicaltrials |
| NCT06727357 | Next Generation Sequencing-based "Oncochip" for Therapeutic Decision in Metastatic Breast Cancer. Study SHARP | active not recruiting | Phase 2 | 38 | European Institute of OncologyOTHER | 1 | Dec 10, 2024 | clinicaltrials |
| NCT03379428 | Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer | active not recruiting | Phase 1 / Phase 2 | 34 | US Oncology ResearchINDUSTRY | 1 | Dec 6, 2024 | clinicaltrials |
| NCT04879563 | Artificial Intelligence Supporting CAncer Patients Across Europe - the ASCAPE Project(ASCAPE) | active not recruiting | Phase 2 | 500 | Region Örebro CountyOTHER | 4 | Nov 19, 2024 | clinicaltrials |
| NCT05426486 | A Study of ARX788 Combined With Pyrotinib Maleate Versus TCBHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients | active not recruiting | Phase 2 / Phase 3 | 136 | Caigang LiuOTHER | 1 | Oct 30, 2024 | clinicaltrials |
| NCT05620134 | Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer | active not recruiting | Phase 1 / Phase 2 | 263 | Salubris Biotherapeutics IncINDUSTRY | 2 | Oct 15, 2024 | clinicaltrials |
| NCT04539496 | A Phase I/II Study of XZP-3287 in Metastasis Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 402 | Sihuan Pharmaceutical Holdings Group Ltd.INDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05710666 | Neoadjuvant Trastuzumab Deruxtecan (T-DXd) With Response-directed Definitive Therapy in Early Stage HER2-positive Breast Cancer (SHAMROCK Study) | active not recruiting | Phase 2 | 11 | Cancer Trials IrelandNETWORK | 1 | Aug 5, 2024 | clinicaltrials |
| NCT06531447 | First-line Gemcitabine Plus Cisplatin in Locally Advanced (IIIC Stage) Breast Cancer Patients | active not recruiting | Phase 2 | 200 | The National Center of Oncology, AzerbaijanOTHER_GOV | 1 | Aug 1, 2024 | clinicaltrials |
| NCT03900637 | PersonaLized neoAdjuvant Strategy ER Positive and HER2 Negative Breast Cancer TO Increase BCS Rate | active not recruiting | Phase 2 | 122 | Seoul National University HospitalOTHER | 1 | Jul 31, 2024 | clinicaltrials |
| NCT05033756 | Comprehensive Analysis of Predictors of the Treatment With Pembrolizumab and Olaparib in Patients With Unresectable or Metastatic HER2 Negative Breast Cancer and a Deleterious Germline Mutation or a Homologous Recombination Deficiency (COMPRENDO(COMPRENDO) | active not recruiting | Phase 2 | 11 | Institut fuer FrauengesundheitOTHER | 1 | May 7, 2024 | clinicaltrials |
| NCT03982485 | Combination Neoadjuvant Chemotherapy With or Without Apatinib for HER2 Negative Breast Cancer(APP) | active not recruiting | Phase 2 | 196 | RenJi HospitalOTHER | 1 | Apr 30, 2024 | clinicaltrials |
| NCT02641847 | TA(E)C-GP Versus A(E)C-T for the High Risk TNBC Patients and Validation of the mRNA-lncRNA Signature | active not recruiting | Phase 2 / Phase 3 | 503 | Fudan UniversityOTHER | 1 | Jan 25, 2024 | clinicaltrials |
| NCT02965950 | The p53 Breast Cancer Trial(p53b) | active not recruiting | Phase 2 | 190 | Haukeland University HospitalOTHER | 1 | Jan 12, 2024 | clinicaltrials |
| NCT04172259 | ACHP-THP vs EC-THP as Neoadjuvant Therapy for HER2-positive EBC | active not recruiting | Phase 2 | 156 | Sun Yat-sen UniversityOTHER | 1 | Oct 16, 2023 | clinicaltrials |
| NCT05569811 | NeoadjuVAnt muLti-agENT Chemotherapy or Patritumab Deruxtecan With or Without endocrINE Therapy for High-risk HR+/HER2- Breast Cancer - VALENTINE Trial(VALENTINE) | active not recruiting | Phase 2 | 120 | SOLTI Breast Cancer Research GroupOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT02221999 | Weekly Paclitaxel and Cisplatin to Treat Hormone Receptor Positive and Triple Negative Breast Cancer Patients(SHPD002) | active not recruiting | Phase 2 / Phase 3 | 250 | RenJi HospitalOTHER | 1 | Aug 29, 2023 | clinicaltrials |
| NCT00909909 | Radiation Therapy in Treating Women With Early Stage Breast Cancer | active not recruiting | Phase 2 | 200 | Rutgers, The State University of New JerseyOTHER | 1 | Aug 3, 2023 | clinicaltrials |
| NCT05824325 | Different Targeted Antibody-drug Conjugates For HER2 Ultra-low or No Expression Advanced Breast Cancer（GALAXY） | active not recruiting | Phase 1 / Phase 2 | 56 | Fudan UniversityOTHER | 1 | Jun 27, 2023 | clinicaltrials |
| NCT02315196 | Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast Cancer | active not recruiting | Phase 2 | 62 | Rutgers, The State University of New JerseyOTHER | 1 | Mar 29, 2023 | clinicaltrials |
| NCT01057069 | Neo Adjuvant Chemotherapy in Triple Negative Breast Cancer(neo-TN) | active not recruiting | Phase 2 / Phase 3 | 310 | The Netherlands Cancer InstituteOTHER | 1 | Oct 12, 2022 | clinicaltrials |
| NCT04486911 | Pyrotinib Maleate, CDK4/6 Inhibitor and Letrozole in Combination for Stage II-III TPBC: a Phase II Trial | active not recruiting | Phase 2 | 89 | Shengjing HospitalOTHER | 1 | Aug 2, 2022 | clinicaltrials |
| NCT02603679 | Neoadjuvant Response-guided Treatment of Luminal B-type Tumors and Luminal A-type Tumors With Node Metastases(PREDIX LumB) | active not recruiting | Phase 2 | 181 | Thomas HatschekOTHER | 1 | Aug 3, 2021 | clinicaltrials |
| NCT02568839 | Neoadjuvant Response-guided Treatment of HER2 Positive Breast Cancer(PREDIX HER2) | active not recruiting | Phase 2 / Phase 3 | 202 | Thomas HatschekOTHER | 1 | Aug 13, 2020 | clinicaltrials |
| NCT02592083 | Neoadjuvant Response-guided Treatment of Slowly Proliferating Hormone Receptor Positive Tumors(PREDIX LumA) | active not recruiting | Phase 2 | 10 | Thomas HatschekOTHER | 1 | Jul 7, 2020 | clinicaltrials |
| NCT02491697 | Immunotherapy Combined With Capecitabine Versus Capecitabine Monotherapy in Advanced Breast Cancer | active not recruiting | Phase 2 | 400 | The First People's Hospital of ChangzhouOTHER | 0 | Feb 23, 2016 | clinicaltrials |
Data updated 23 days agoSource updated Jun 4, 2025source: clinicaltrials